Wave Life Sciences Ltd.

Good morning and welcome to the Wave Life Sciences first quarter 2024 financial results conference call. At this time, all participants are on a listen-only mode. As a reminder, this call is being recorded in webcast. I would now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Thank you, Kevin. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's first quarter 2024 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer, Kyle Moran, Chief Financial Officer, and Anne-Marie Lee-Kwai Chung, Chief Development Officer. The press release issued this morning is available on the Investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filing. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul.

Thanks, Kate. Good morning, and thank you all for joining us on today's call. I will open with comments on our recent progress and continued execution on our strategy. Next, Ann Marie will provide an update on our three ongoing clinical trials. And before opening up the call for questions, Kyle will review our financials.